New radioactive tracer could spot breast cancer without a biopsy

NCT ID NCT05203497

Completed Diagnosis Sponsor: Tomsk National Research Medical Center of the Russian Academy of Sciences Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new radioactive tracer called 99mTc-ZHER2:41071 in 30 women with breast cancer. The tracer is designed to attach to HER2 proteins on cancer cells, allowing doctors to see them on a SPECT scan. The goal was to see how the tracer spreads in the body, how safe it is, and whether it can accurately tell HER2-positive from HER2-negative tumors compared to standard biopsy tests.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Technetium-99m-labeled affibody molecule (99mTc-ZHER2:41071)
What this could lead to: If successful, this could lead to a non-invasive imaging method to detect HER2-positive breast cancer, potentially reducing the need for biopsies.
What could go wrong: This is an early phase 1 study with only 30 participants, so results may not apply to all patients. The tracer's safety and accuracy are still being tested.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER FEMALE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm female breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER FEMALE

Contacts and locations

Locations

TomskNRMC

Tomsk, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.